annual net income:
-$278.16M+$162.09M(+36.82%)Summary
- As of today (April 19, 2025), ALNY annual net profit is -$278.16 million, with the most recent change of +$162.09 million (+36.82%) on December 31, 2024.
- During the last 3 years, ALNY annual net income has risen by +$574.67 million (+67.38%).
- ALNY annual net income is now -6625.27% below its all-time high of -$4.14 million, reached on December 31, 2002.
Performance
ALNY Net income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly net income:
-$83.76M+$27.81M(+24.92%)Summary
- As of today (April 19, 2025), ALNY quarterly net profit is -$83.76 million, with the most recent change of +$27.81 million (+24.92%) on December 31, 2024.
- Over the past year, ALNY quarterly net income has increased by +$54.11 million (+39.24%).
- ALNY quarterly net income is now -156.69% below its all-time high of $147.75 million, reached on September 30, 2023.
Performance
ALNY quarterly net income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM net income:
-$278.16M+$54.11M(+16.28%)Summary
- As of today (April 19, 2025), ALNY TTM net profit is -$278.16 million, with the most recent change of +$54.11 million (+16.28%) on December 31, 2024.
- Over the past year, ALNY TTM net income has increased by +$162.09 million (+36.82%).
- ALNY TTM net income is now -12831.52% below its all-time high of -$2.15 million, reached on March 31, 2003.
Performance
ALNY TTM net income Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Net income Formula
Net Income = Revenue − COGS − Operating Expenses − Interest − Taxes − Other Expenses
ALNY Net income Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +36.8% | +39.2% | +36.8% |
| 3 y3 years | +67.4% | +39.2% | +36.8% |
| 5 y5 years | +68.6% | +39.2% | +36.8% |
ALNY Net income Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +75.4% | -156.7% | +79.4% | -281.4% | +76.5% |
| 5 y | 5-year | at high | +75.4% | -156.7% | +79.4% | -281.4% | +76.5% |
| alltime | all time | -6625.3% | +75.4% | -156.7% | +79.4% | <-9999.0% | +76.5% |
Alnylam Pharmaceuticals Net income History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2024 | -$278.16M(-36.8%) | -$83.76M(-24.9%) | -$278.16M(-16.3%) |
| Sep 2024 | - | -$111.57M(+560.6%) | -$332.26M(+355.5%) |
| Jun 2024 | - | -$16.89M(-74.4%) | -$72.94M(-78.0%) |
| Mar 2024 | - | -$65.94M(-52.2%) | -$332.08M(-24.6%) |
| Dec 2023 | -$440.24M(-61.1%) | -$137.87M(-193.3%) | -$440.24M(-13.7%) |
| Sep 2023 | - | $147.75M(-153.5%) | -$509.87M(-52.1%) |
| Jun 2023 | - | -$276.02M(+58.5%) | -$1.06B(-0.1%) |
| Mar 2023 | - | -$174.10M(-16.1%) | -$1.06B(-5.9%) |
| Dec 2022 | -$1.13B(+32.6%) | -$207.49M(-48.9%) | -$1.13B(-4.3%) |
| Sep 2022 | - | -$405.92M(+46.3%) | -$1.18B(+20.5%) |
| Jun 2022 | - | -$277.40M(+15.4%) | -$980.72M(+9.8%) |
| Mar 2022 | - | -$240.34M(-7.0%) | -$892.87M(+4.7%) |
| Dec 2021 | -$852.82M(-0.6%) | -$258.46M(+26.4%) | -$852.82M(+1.8%) |
| Sep 2021 | - | -$204.51M(+7.9%) | -$837.90M(-5.5%) |
| Jun 2021 | - | -$189.56M(-5.4%) | -$886.68M(+1.2%) |
| Mar 2021 | - | -$200.29M(-17.8%) | -$876.35M(+2.1%) |
| Dec 2020 | -$858.28M(-3.1%) | -$243.54M(-3.8%) | -$858.28M(-3.7%) |
| Sep 2020 | - | -$253.29M(+41.3%) | -$890.93M(+5.3%) |
| Jun 2020 | - | -$179.23M(-1.6%) | -$846.17M(-4.5%) |
| Mar 2020 | - | -$182.22M(-34.0%) | -$886.42M(+0.0%) |
| Dec 2019 | -$886.12M(+16.4%) | -$276.19M(+32.4%) | -$886.12M(+7.9%) |
| Sep 2019 | - | -$208.53M(-5.0%) | -$821.37M(-4.3%) |
| Jun 2019 | - | -$219.48M(+20.7%) | -$858.12M(+7.0%) |
| Mar 2019 | - | -$181.91M(-14.0%) | -$802.20M(+5.3%) |
| Dec 2018 | -$761.50M(+55.1%) | -$211.44M(-13.8%) | -$761.50M(+10.0%) |
| Sep 2018 | - | -$245.28M(+50.0%) | -$692.28M(+21.5%) |
| Jun 2018 | - | -$163.56M(+15.8%) | -$569.94M(+8.6%) |
| Mar 2018 | - | -$141.21M(-0.7%) | -$524.80M(+6.9%) |
| Dec 2017 | -$490.87M(+19.7%) | -$142.23M(+15.7%) | -$490.87M(+6.3%) |
| Sep 2017 | - | -$122.94M(+3.8%) | -$461.58M(+4.3%) |
| Jun 2017 | - | -$118.42M(+10.4%) | -$442.71M(+6.8%) |
| Mar 2017 | - | -$107.29M(-5.0%) | -$414.42M(+1.1%) |
| Dec 2016 | -$410.11M(+41.4%) | -$112.93M(+8.5%) | -$410.11M(+5.7%) |
| Sep 2016 | - | -$104.07M(+15.5%) | -$387.89M(+7.6%) |
| Jun 2016 | - | -$90.13M(-12.5%) | -$360.62M(+5.4%) |
| Mar 2016 | - | -$102.97M(+13.5%) | -$342.27M(+18.0%) |
| Dec 2015 | -$290.07M(-19.5%) | -$90.72M(+18.1%) | -$290.07M(+31.4%) |
| Sep 2015 | - | -$76.79M(+7.0%) | -$220.74M(+17.5%) |
| Jun 2015 | - | -$71.78M(+41.4%) | -$187.94M(+17.3%) |
| Mar 2015 | - | -$50.78M(+137.4%) | -$160.23M(-55.5%) |
| Dec 2014 | -$360.39M(+303.9%) | -$21.39M(-51.4%) | -$360.39M(-3.0%) |
| Sep 2014 | - | -$43.99M(-0.2%) | -$371.36M(+4.0%) |
| Jun 2014 | - | -$44.07M(-82.4%) | -$357.06M(+7.8%) |
| Mar 2014 | - | -$250.94M(+675.5%) | -$331.15M(+271.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2013 | -$89.22M(-15.8%) | -$32.36M(+9.0%) | -$89.22M(-25.1%) |
| Sep 2013 | - | -$29.69M(+63.4%) | -$119.06M(+9.4%) |
| Jun 2013 | - | -$18.17M(+101.6%) | -$108.87M(+5.0%) |
| Mar 2013 | - | -$9.01M(-85.5%) | -$103.66M(-2.2%) |
| Dec 2012 | -$106.01M(+83.9%) | -$62.19M(+218.9%) | -$106.01M(+82.4%) |
| Sep 2012 | - | -$19.50M(+50.5%) | -$58.13M(+12.1%) |
| Jun 2012 | - | -$12.96M(+14.0%) | -$51.86M(-1.6%) |
| Mar 2012 | - | -$11.37M(-20.5%) | -$52.73M(-8.5%) |
| Dec 2011 | -$57.65M(+32.5%) | -$14.30M(+8.1%) | -$57.65M(+14.7%) |
| Sep 2011 | - | -$13.24M(-4.2%) | -$50.28M(+7.7%) |
| Jun 2011 | - | -$13.82M(-15.1%) | -$46.67M(-1.7%) |
| Mar 2011 | - | -$16.29M(+135.0%) | -$47.48M(+9.1%) |
| Dec 2010 | -$43.52M(-8.6%) | -$6.93M(-28.0%) | -$43.52M(-1.9%) |
| Sep 2010 | - | -$9.63M(-34.2%) | -$44.38M(+1.0%) |
| Jun 2010 | - | -$14.63M(+18.7%) | -$43.95M(-15.5%) |
| Mar 2010 | - | -$12.32M(+58.2%) | -$52.02M(+9.3%) |
| Dec 2009 | -$47.59M(+81.3%) | -$7.79M(-15.4%) | -$47.59M(-3.3%) |
| Sep 2009 | - | -$9.21M(-59.4%) | -$49.19M(+14.8%) |
| Jun 2009 | - | -$22.70M(+187.8%) | -$42.84M(+30.2%) |
| Mar 2009 | - | -$7.89M(-16.0%) | -$32.90M(+25.3%) |
| Dec 2008 | -$26.25M(-69.3%) | -$9.39M(+228.6%) | -$26.25M(+72.7%) |
| Sep 2008 | - | -$2.86M(-77.6%) | -$15.20M(-76.7%) |
| Jun 2008 | - | -$12.76M(+929.9%) | -$65.13M(+0.1%) |
| Mar 2008 | - | -$1.24M(-174.5%) | -$65.06M(-23.9%) |
| Dec 2007 | -$85.47M(+147.0%) | $1.66M(-103.1%) | -$85.47M(-10.6%) |
| Sep 2007 | - | -$52.79M(+316.0%) | -$95.57M(+90.5%) |
| Jun 2007 | - | -$12.69M(-41.4%) | -$50.17M(+5.9%) |
| Mar 2007 | - | -$21.64M(+156.5%) | -$47.39M(+36.9%) |
| Dec 2006 | -$34.61M(-19.4%) | -$8.44M(+14.0%) | -$34.61M(-14.9%) |
| Sep 2006 | - | -$7.40M(-25.3%) | -$40.66M(-7.5%) |
| Jun 2006 | - | -$9.91M(+11.9%) | -$43.94M(-2.7%) |
| Mar 2006 | - | -$8.86M(-38.9%) | -$45.17M(+5.3%) |
| Dec 2005 | -$42.91M(+31.4%) | -$14.49M(+35.7%) | -$42.91M(+25.8%) |
| Sep 2005 | - | -$10.68M(-4.2%) | -$34.12M(+14.3%) |
| Jun 2005 | - | -$11.14M(+68.9%) | -$29.86M(+16.3%) |
| Mar 2005 | - | -$6.60M(+15.8%) | -$25.67M(-21.4%) |
| Dec 2004 | -$32.65M(+30.4%) | -$5.70M(-11.2%) | -$32.65M(-1.7%) |
| Sep 2004 | - | -$6.42M(-7.8%) | -$33.21M(+0.5%) |
| Jun 2004 | - | -$6.96M(-48.8%) | -$33.05M(+12.7%) |
| Mar 2004 | - | -$13.58M(+117.0%) | -$29.34M(+63.8%) |
| Dec 2003 | -$25.03M(+505.2%) | -$6.26M(0.0%) | -$17.91M(+53.7%) |
| Sep 2003 | - | -$6.26M(+92.9%) | -$11.65M(+116.0%) |
| Jun 2003 | - | -$3.24M(+50.8%) | -$5.39M(+150.8%) |
| Mar 2003 | - | -$2.15M | -$2.15M |
| Dec 2002 | -$4.14M | - | - |
FAQ
- What is Alnylam Pharmaceuticals annual net profit?
- What is the all time high annual net income for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual net income year-on-year change?
- What is Alnylam Pharmaceuticals quarterly net profit?
- What is the all time high quarterly net income for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly net income year-on-year change?
- What is Alnylam Pharmaceuticals TTM net profit?
- What is the all time high TTM net income for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals TTM net income year-on-year change?
What is Alnylam Pharmaceuticals annual net profit?
The current annual net income of ALNY is -$278.16M
What is the all time high annual net income for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual net profit is -$4.14M
What is Alnylam Pharmaceuticals annual net income year-on-year change?
Over the past year, ALNY annual net profit has changed by +$162.09M (+36.82%)
What is Alnylam Pharmaceuticals quarterly net profit?
The current quarterly net income of ALNY is -$83.76M
What is the all time high quarterly net income for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly net profit is $147.75M
What is Alnylam Pharmaceuticals quarterly net income year-on-year change?
Over the past year, ALNY quarterly net profit has changed by +$54.11M (+39.24%)
What is Alnylam Pharmaceuticals TTM net profit?
The current TTM net income of ALNY is -$278.16M
What is the all time high TTM net income for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high TTM net profit is -$2.15M
What is Alnylam Pharmaceuticals TTM net income year-on-year change?
Over the past year, ALNY TTM net profit has changed by +$162.09M (+36.82%)